INTRODUCTION
Primary bone tumors are part of a large family of bone tumors including malignant and benign entities [1] . Bone sarcomas are malignant primary bone tumors with a common cellular origin. Osteosarcoma, which is the most frequent malignant bone tumor, originates from mesenchymal stem cells and has a common origin with Ewing's sarcoma and chondrosarcoma [1, 2] . The current standard therapeutic approach to osteosarcoma is based on preoperative chemotherapy with a cocktail of 3 to 4 drugs (generally adriamycin, platinumrelated drugs and methotrexate) followed by delayed en-bloc wide resection for histologic assessment. After preoperative chemotherapy, patients are categorized as good and poor responders depending on the residual tumor cells in the resected tumor tissue [3] . This protocol was initially proposed by Rosen et al. at the end of the 1980s and made it possible to improve patient life expectancy and to avoid amputation of the limb in question [4] . Despite recent improvements in surgery and the development of different regimens of multi-drug chemotherapy over the last 3 decades, the long-term survival rate remains around 55-70% at 5 years according to published series [5, 6] .
Unfortunately, the natural history of osteosarcoma is still mostly unknown, despite the fact that considerable efforts have been made by the medical community to identify new biomarkers that will be used to predict the therapeutic response of patients prior to the initiation of therapy or to adapt the drug regimen in case of recurrent disease [7] .
Nevertheless, in the last few years, various therapeutic targets have been suggested and are at the origin of customized therapies [8, 9] . Drugs against protagonists of signaling pathways have been developed extensively and entered very quickly into clinical trials. Almost cell signaling induced by cytokines/growth factors involves the PI3K/mTOR pathway, small synthetic inhibitors of these targets have been produced [10] [11] [12] [13] . However, resistance mechanisms to mTOR inhibitors and the high frequency for mutation and/or gain in function of PI3K catalytic subunits in cancer cells has led to the development of dual PI3K/mTOR inhibitors such as NVP-BEZ235 [14] . NVP-BEZ235 is an imidazol [4, 5] quinolone derivative which specifically targets the ATP-binding sites of PI3K and mTOR enzymes. Although NVP-BEZ235 has shown promising therapeutic activity in carcinomas [15, 16] and lymphomas [17] , only a few reports are available for bone sarcomas [18, 19] , and, more specifically, osteosarcomas. For this report, the efficiency of NVP-BEZ235 was studied in vitro in 4 human and murine cell lines and in two models (syngenic and xenogenic) of osteosarcoma where tumor growth, bone histomorphometry and histology were assessed.
MATERIALS AND METHODS

Reagent
NVP-BEZ235 was kindly provided by Pharma Novartis (Basel, Switzerland). Stock solution (10 mM) was prepared in 100 % of DMSO for the in vitro experiments. For mice, NVP-BEZ235 was dissolved in 10 % of 1-Methyl-2-pyrrolidinone (NMP; Sigma) + 90 % of PEG300 (Sigma).
Cell lines and culture conditions
Human osteosarcoma MG-63 and HOS-MNNG (HOS) cells purchased from ATCC (USA) and rat osteosarcoma OSRGA cells [20] were cultured in DMEM (Lonza, Belgium) supplemented with 5% of Fetal Bovine Serum (FBS; Hyclone Perbio, France). Murine osteosarcoma POS-1 and MOS-J cells were provided by Drs Kamijo [21] and Shultz [22] respectively and cultured in RPMI (Lonza, Belgium) supplemented with 5% of FBS.
Cell growth and viability
Two thousand cells were seeded into 96-well plates and cultured for 72 hours with or without NVP-BEZ235 (1 to 200 nmol/L). Cell growth and viability were determined by a colorimetric assay using the XTT reagent assay kit (Roche Molecular Biochemicals, Germany). Cell viability was also determined by means of trypan blue exclusion assay; viable and non-viable cells were counted manually after 24 and 48 hours of treatment.
Caspase activity
Two hundred thousand cells were seeded in 6-well plates and cultured with or without NVP-BEZ235 for 3 to 48 hours (25 µM). Caspase activity was assessed on 10 µl of whole cell lysates using the CaspACE Assay System kit (Promega), in accordance with the manufacturer's recommendations. The results were expressed in arbitrary units, and corrected for protein concentration quantified by Bicinchoninic acid assay (Sigma). The lysate of cells treated with 1µg/ml of Staurosporine (Invitrogen) overnight was used as the positive control.
Cell cycle analysis
Subconfluent cultures were incubated with or without 200 nM of NVP-BEZ235 for 24 hours, trypsinized, washed and incubated in PBS containing 0.12% of Triton X-100, 0.12 mM of EDTA and 100 µg/ml of ribonuclease A DNase-free (Sigma). Then, 50 µg/ml of Propidium Iodide (IP; Promega) were added for 20 minutes. Cell cycle distribution was determined by means of flow cytometry (Cytomics FC500; Beckman Coulter), based on 2N and 4N DNA content, and analyzed using DNA Cell Cycle Analysis Software (Phoenix Flow System, San Diego, CA, USA). Tumors appeared at the injection site 8 days later and led to osteoblastic lesions reproducing the osteoblastic form of human osteosarcoma [23] .
Cell signaling analysis
Xenogenic model of osteoblastic osteosarcoma:
Five-week-old female Rj:NMRI-nude mice were anesthetized as previously described before an i.m. inoculation of 2 x 10 6 human HOS osteosarcoma cells.
The mice were sacrificed by cervical dislocation for ethical reasons when the tumor volume reached 2000 mm 3 . For both models, tumor volumes were calculated by measuring two perpendicular diameters using calipers, according to the following formula: V=0.5xLx(S) 2 , in which L and S are, respectively, the largest and the smallest perpendicular diameters as previously described [23] . The bone microarchitecture was analyzed using the high-resolution X-ray micro-computed tomography (CT) system for small animal imaging Sky-Scan-1076
(SkyScan, Belgium). Analyses were performed at necropsy (tumor volume 2000 mm 3 ,
according with the recommendations of the Ethical Committee). All tibiae were scanned using the same parameters (pixel size 18 µm, 50 kV, 0.5 mm aluminum filter and 0.8 degree of rotation step). Three-dimensional reconstructions were made using CTvox software (Skyscan). Two-dimensional analyses of the bone parameters were performed on 200 layers (cortical aera) using the CTan software (Skyscan 
Bone histology and immunohistochemistry
After euthanasia, the tibiae were preserved and fixed in 10% of PFA, decalcified with 13% of EDTA, and 0.2% of PFA in PBS using a microwave tissue processor (KOS, Mikron
Instruments, USA) for 5 to 7 days and embedded in paraffin. 3 µm sections were cut and stained using the Masson-trichrome method [23] . For TRAP staining, serial 4 µm-thick sagittal sections were prepared and stained to identify osteoclasts following1hour of incubation in a solution composed of 1 mg/mL of naphthol AS-TR phosphate, 60 mM of NNdimethylformamide, 100 mM of sodium tartrate, and 1 mg/mL of Fast red TR salt solution (Sigma) [24] . The staining surface was quantified using ImageJ (NIH, USA).
Immunohistochemistry was carried out on 3mm-thick deparaffinized sections as described previously. The sections were incubated with diluted goat corresponding primary antibody (Supplementary data 1) for 1 hour. Positive immunostaining was quantified using Qwin software (Leica).
Statistical Analysis
Each experiment was repeated independently 3 times. The results are given as a mean ± standard deviation (SD) (in vitro experiments) and mean ± SEM (in vivo experiments) and were compared using the Unpaired t test or ANOVA followed by the Bonferroni post test using Graph Pad InStat v3.02 software. Results with p<0.05 were considered significant.
RESULTS
NVP-BEZ235 is a powerful drug that inhibits the proliferation of osteosarcoma cells
We first assessed the ability of NVP-BEZ235 ( Figure 1A ) to modulate the signaling pathway in osteosarcoma cells. As expected, NVP-BEZ235 considerably decreased the levels of both AKT and mTOR phosphorylation in a dose-( Figure 1B ) and time-dependent ( Figure 1C Figure 3C ). This qualitative observation was confirmed by histomorphometry which showed a significant decrease in the BS (p<0.001) and BV (p<0.01) of the tumor ectopic bone formed with 45 mg/kg/day NVP-BEZ235 compared to the control group ( Figure 3D ).
NVP-BEZ235 slows down osteosarcoma growth in a xenogenic model and increases the survival rate
The therapeutic value of NVP-BEZ235 was analyzed in a xenogenic model of osteosarcoma. and nude mice (Supplemental data 4), excepting a slight decrease in cortical thickness in C57Bl/6J and a slight increase in bone surface density (Supplementary Table 3) . Surprisingly, histological assessment revealed that NVP-BEZ235 significantly increased the number of TRAP + cells and decreased osterix + cells in C57BL/6J mice after three weeks of treatment ( Figure 6 ).
DISCUSSION
It is widely admitted that the development of bone sarcomas is controlled by the tumor cell environment, called the bone niche. This concept is based on the "seed and soils" theory proposed by Paget in 1887 in which tumor cells ("seeds") are said to colonize receptive foci ("soils"). The soil is composed of extracellular matrix and various cells releasing cytokines and growth factors which activate numerous signaling pathways through their binding to tyrosine kinase receptors (IGF1, PDGFR, etc) or/and kinases associated with other membrane receptors [9, 26] . The PI3K/mTOR pathway is one of these signaling pathways and regulates many basic biological processes (cell proliferation, survival, migration, glucose metabolism, and nutriment sensors) [11, 27] . The PI3K pathway is involved in the proliferation and migration of osteosarcoma cells and appears to induce an anti-apoptotic signal associated with resistance to conventional drugs [23, [28] [29] [30] [31] [32] .
Our work confirms that NVP-BEZ235 inhibits osteosarcoma cell proliferation by inducing a cell cycle arrest in the G0/G1 phase without induction of cell death. We demonstrated the therapeutic value of this dual PI3K/mTOR inhibitor in two murine preclinical models of osteosarcoma, regardless of the immune status of the animals used. The therapeutic benefit was associated with a considerable decrease in Ki67 + cells and tumor vasculature. Ki67 recognizes a nuclear antigen and the expression of Ki67 varies throughout the cell cycle [33] . These variations appear to reflect de novo synthesis rather than an accumulation of non-degraded proteins. In fact, the Ki67 level, which has a short half-life for this marker, is low during the G1 and early S phase and rises to its peak level in mitosis [34] .
As a result, a decrease in Ki67 is directly related to cell proliferation, an observation that is in line with the cell cycle arrest in G0/G1 observed after NVP-BEZ235 treatment and reinforced by its considerable inhibition of Ki67 + in vivo.
Most tumor growth requires neoangiogenesis to deliver nutrients and oxygen to the cells, and facilitates the extravasation of cancer cells which can migrate, colonize various organs and therefore form metastases. CD146, inhibited after NVP-BEZ235 treatment in mice with osteosarcomas, has been identified as an endothelial cell adhesion molecule implicated in blood vessel formation and acts as a co-receptor for VEGFR-2 in tumor angiogenesis [35, 36] .
Immunohistochemistry revealed the high expression of CD146 in osteosarcomas related to the We studied the impact of NVP-BEZ235 treatment on the histomorphometric parameters of bone. While µCT analyses did not reveal any major effects of the drug, histologic assessment identified deregulation between osteoclasts and osteoblasts as shown by an increase in the TRAP + cell surface and the down-regulation of osterix + cell numbers. This finding may appear somewhat contradictory. However, to date, the role of the PI3K/mTOR pathway in osteogenesis has remained controversial because conflicting studies using mTOR inhibitors have reported both negative and positive effects and their effects are cross-linked to the hormonal status of patients [38] . Similarly, Martin et al. recently reported that NVP-BEZ235 promotes human osteogenic differentiation at the same time as a considerable upregulation of Noggin, a BMP antagonist inhibiting in vivo osteogenesis [39, 40] . This effect appears to be a local feedback mechanism to temper BMP activities. Furthermore, high concentrations of NVP-BEZ235 (> 530 nM) totally inhibit the proliferation of osteoblast progenitors in favor of a reduced osteogenesis [39] . Canalis et al. demonstrated that osteoblast-specific conditional null Noggin mice had osteopenia and hypothesized a BMPindependent role of Noggin in skeletal homeostasis [41] . In addition, in these mice, the authors showed that osteoclast numbers increased in 1-month-old male Noggin conditional null mice and that bone formation increased in 3-month-old mice. The effect of NVP-BEZ235 may be due to BMP-dependent and independent activities of Noggin after several weeks of administration which remain not fully understood. Additional experiments are required to better understand the long term effect of PI3K/mTOR inhibitors on bone remodeling.
Overall, our data provide evidence that PI3K/mTOR pathway is a potential target for treating osteosarcoma. Due to the lack of apoptotic activity, NVP-BEZ235 is promising as an adjuvant drug for bone sarcomas.
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